Emotional disorders induced by Hemopressin and RVD-hemopressin(α) administration in rats
Authors:
- Sheila LeoneSheila Leone
- Lucia RecinellaLucia Recinella
- Annalisa ChiavaroliAnnalisa Chiavaroli
- Claudio FerranteClaudio Ferrante
- Adriano MollicaAdriano Mollica
- Giorgia MacedonioGMGiorgia Macedonio
- Azzurra StefanucciAzzurra Stefanucci
- Csaba TömbölyCTCsaba Tömböly
- Luciano De PetrocellisLPLuciano De Petrocellis
- Michele VaccaMVMichele Vacca
- 1 December 2017
- journal article
- Published by Springer Nature in Pharmacological Reports
- Vol. 69 (6) , 1247-1253
Abstract
The endocannabinoid (eCB) system plays an important role in regulating emotional disorders, and is involved, directly or indirectly, in psychiatric diseases, such as anxiety and depression. Hemopressin, a hemoglobin α chain-derived peptide, and RVD-hemopressin(α), a N-terminally extended form of hemopressin, act as antagonist/inverse agonist and negative allosteric modulator of the cannabinoid 1 (CB1) receptor, respectively. Considering the possible involvement of these peptides on emotional behaviour, the aim of our study was to investigate the behavioural effects of a single intraperitoneal (ip) injection of hemopressin (0.05mg/kg) and RVD-hemopressin(α) (0.05mg/kg), using a series of validated behavioural tests (locomotor activity/open field test, light-dark exploration test, forced swim test) in rats. Prefrontal cortex levels of norepinephrine (NE), dopamine (DA) and serotonin (5-hydroxytryptamine, 5-HT) and the gene expression of monoamine oxidase (MAO-B) and catechol-O-methyltransferase (COMT) were measured by high performance liquid chromatography (HPLC) analysis and real-time reverse transcription polymerase chain reaction (RT-PCR), respectively. Hemopressin administration induced anxiogenic and depressive behaviour, decreased monoamine steady state levels in prefrontal cortex, and increased the gene expression of the enzymes involved in their catabolism. By contrast, RVD- hemopressin(α) induced anxiolytic and antidepressive effects, increased monoamines and decreased the enzymes in prefrontal cortex. In conclusion, in the present study we demonstrated behavioral effects induced by peripheral hemopressin and RVD-hemopressin(α) injections, that could involve modulatory effects on monoaminergic signaling, in the prefrontal cortex.Keywords
Funding Information
- ÚNKP-16-3 New National Excellence Program of the Ministry of Human Capacities of Hungary
This publication has 52 references indexed in Scilit:
- Endocannabinoids and Mental Disorders2015
- Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric diseaseExpert Opinion on Drug Discovery, 2014
- Cannabinoids and monoamine neurotransmission with focus on monoamine oxidaseProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2012
- Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systemsJournal of Psychopharmacology, 2010
- The psychiatric side-effects of rimonabantBrazilian Journal of Psychiatry, 2009
- Novel endogenous peptide agonists of cannabinoid receptorsThe FASEB Journal, 2009
- Serum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary ReportPharmacopsychiatry, 2008
- Hemopressin is an inverse agonist of CB 1 cannabinoid receptorsProceedings of the National Academy of Sciences, 2007
- Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depressionJournal of Neural Transmission, 2007
- Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victimsMolecular Psychiatry, 2004